← Back to Search

Behavioral Intervention

Vaccine Education for COVID-19

N/A
Waitlist Available
Led By Klaus Heyer, PhD
Research Sponsored by Xavier University of Louisiana.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Individuals with incomplete vaccination (primary series or COVID-19 booster)
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 9 months intervention
Awards & highlights

Study Summary

This trial will test a new way of educating people about vaccines in order to get more people to get the vaccine, specifically in vulnerable communities in Louisiana.

Who is the study for?
This trial is for adults aged 18-99 in Southeastern Louisiana who are not fully vaccinated against COVID-19, including those needing primary series or boosters. Participants must be able to consent and communicate in English, Spanish, or Arabic. Fully vaccinated individuals or those allergic to vaccine components cannot join.Check my eligibility
What is being tested?
The study tests a rapid vaccination education model delivered at the point of COVID-19 testing by healthcare personnel. It aims to increase vaccine completion rates among patients seeking testing at pharmacies, urgent cares, and clinics.See study design
What are the potential side effects?
Since this trial focuses on education rather than administering vaccines directly, it does not have medical side effects. However, participants may experience increased awareness and knowledge about COVID-19 vaccines.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You have not completed your required COVID-19 vaccinations.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~9 months intervention
This trial's timeline: 3 weeks for screening, Varies for treatment, and 9 months intervention for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
COVID-19 Vaccine Completion
Secondary outcome measures
Vaccine Hesitancy Likelihood Scale

Trial Design

1Treatment groups
Experimental Treatment
Group I: Participants Which Receive COVID-19 Vaccine Education at the Point of COVID-19 TestingExperimental Treatment1 Intervention
Vaccine education will be focused on addressing misinformation and concerns in a culturally competent manner with referral to resources. The vaccine education model will be translated to reach minority groups including African Americans, Vietnamese Americans and Hispanic Americans.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
COVID-19 Vaccine Education at the Point of COVID-19 Testing
2022
N/A
~380

Find a Location

Who is running the clinical trial?

Xavier University of Louisiana.Lead Sponsor
6 Previous Clinical Trials
2,449 Total Patients Enrolled
Klaus Heyer, PhDPrincipal InvestigatorNunez Community College
1 Previous Clinical Trials
450 Total Patients Enrolled
Sara Al-Dahir, PharmDPrincipal InvestigatorXavier University of Louisiana.

Media Library

COVID-19 Vaccine Education at the Point of COVID-19 Testing (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT04939506 — N/A
Coronavirus Research Study Groups: Participants Which Receive COVID-19 Vaccine Education at the Point of COVID-19 Testing
Coronavirus Clinical Trial 2023: COVID-19 Vaccine Education at the Point of COVID-19 Testing Highlights & Side Effects. Trial Name: NCT04939506 — N/A
COVID-19 Vaccine Education at the Point of COVID-19 Testing (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04939506 — N/A
Coronavirus Patient Testimony for trial: Trial Name: NCT04939506 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are new participants still being sought to take part in this clinical experiment?

"Per the information listed on clinicaltrials.gov, this medical study is no longer in search of applicants. It was first published on January 1st 2022 and was last revised June 24th 2021; however, there are currently 1055 other trials actively searching for participants at this time."

Answered by AI

Can individuals aged eighty-five and over participate in this clinical trial?

"The eligibility requirements of this trial indicate that the minimum age for participation is 18, while the maximum age applicable to participants is 99."

Answered by AI

What type of participant is ideal for this research endeavor?

"This clinical trial is accepting participants with vaccine hesitancy who range from 18 to 99 years old. 375 individuals have been recruited so far, and the team plans to continue recruiting more."

Answered by AI

Who else is applying?

What state do they live in?
Louisiana
What site did they apply to?
Xavier University of Louisiana
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
2

Why did patients apply to this trial?

Hesitant about getting the booster.
PatientReceived no prior treatments
~152 spots leftby Mar 2025